Literature DB >> 10972374

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

H Van den Hout, A J Reuser, A G Vulto, M C Loonen, A Cromme-Dijkhuis, A T Van der Ploeg.   

Abstract

Pompe's disease is a fatal muscular disorder caused by lysosomal alpha-glucosidase deficiency. In an open-label study, four babies with characteristic cardiomyopathy were treated with recombinant human alpha-glucosidase (rhGAA) from rabbit milk at starting doses of 15 mg/kg or 20 mg/kg, and later 40 mg/kg. The enzyme was generally well tolerated. Activity of alpha-glucosidase normalised in muscle. Tissue morphology and motor and cardiac function improved. The left-ventricular-mass index decreased significantly. We recommend early treatment. Long-term effects are being studied.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972374     DOI: 10.1016/s0140-6736(00)02533-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  89 in total

Review 1.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 2.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Progress and problems when considering gene therapy for GSD-II.

Authors:  A Kiang; A Amalfitano
Journal:  Acta Myol       Date:  2007-07

4.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.

Authors:  A J McVie-Wylie; K L Lee; H Qiu; X Jin; H Do; R Gotschall; B L Thurberg; C Rogers; N Raben; M O'Callaghan; W Canfield; L Andrews; J M McPherson; R J Mattaliano
Journal:  Mol Genet Metab       Date:  2008-06-05       Impact factor: 4.797

5.  Enzyme replacement in neuronal storage disorders in the pediatric population.

Authors:  Erika F Augustine; Jonathan W Mink
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

6.  Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.

Authors:  Nina Raben; Kanneboyina Nagaraju; Alicia Lee; Nina Lu; Yesenia Rivera; Tejas Jatkar; John J Hopwood; Paul H Plotz
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

7.  Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.

Authors:  Jami C Levine; Priya S Kishnani; Y T Chen; J Rene Herlong; Jennifer S Li
Journal:  Pediatr Cardiol       Date:  2008-07-26       Impact factor: 1.655

8.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

9.  Adult onset glycogen storage disease type II (adult onset Pompe disease): report and magnetic resonance images of two cases.

Authors:  Andrew Del Gaizo; Sima Banerjee; Michael Terk
Journal:  Skeletal Radiol       Date:  2009-12       Impact factor: 2.199

10.  Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.

Authors:  Michael Beck
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.